Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955238051> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2955238051 endingPage "542" @default.
- W2955238051 startingPage "542" @default.
- W2955238051 abstract "Background: Tazarotene has been extensively studied in clinical trials and is widely used to treat acne vulgaris (acne). Irritation potential has limited its use. Objective: To compare efficacy, safety, and tolerability of a novel formulation tazarotene 0.045% lotion based on polymeric emulsion technology, and tazarotene 0.1% cream in patients with moderate-to-severe acne. Methods: A total of 210 patients, 12 years and older were randomized to receive tazarotene 0.045% lotion, tazarotene 0.1% cream, or respective vehicle in double-blind, randomized, vehicle-controlled, 12-week study evaluating safety and efficacy (inflammatory and noninflammatory lesion counts and using Evaluator Global Severity Scores [EGSS]). In addition, patients completed a patient satisfaction survey (PSS), and acne-specific quality of life (QoL) questionnaire. Safety and cutaneous tolerability were assessed throughout. Results: A novel tazarotene 0.045% lotion demonstrated statistically significant superiority to vehicle in reducing inflammatory and noninflammatory lesion counts (P=.006 and P<.001) and clearly more effective in treatment success at week 12. In addition, at less than half the concentration, tazarotene 0.045% lotion was numerically more effective than tazarotene 0.1% cream. Mean percent reductions in inflammatory and noninflammatory lesions were 63.8% and 56.9%, compared with 60.0% and 54.1% with tazarotene 0.1% cream at week 12. Treatment success assessed by the investigator or patients’ self-assessment was also numerically greater with tazarotene 0.045% lotion. There were no significant differences in patient satisfaction or QoL between the two active treatments. Both were well-tolerated, however, there were more treatment-related adverse events with tazarotene 0.1% cream (5.6% versus 2.9%); most common being application site pain. Limitations: This study was primarily designed to direct the phase 3 program and some of the results are post hoc analyses. Conclusions: A novel tazarotene 0.045% lotion provides statistically significant greater efficacy than vehicle in terms of lesion reduction, and numerically better treatment success than tazarotene 0.1% cream; with a highly favorable safety and tolerability profile in moderate-to-severe acne patients. J Drugs Dermatol. 2019;18(6):542-548." @default.
- W2955238051 created "2019-07-12" @default.
- W2955238051 creator A5024204845 @default.
- W2955238051 creator A5027145121 @default.
- W2955238051 creator A5028916171 @default.
- W2955238051 creator A5043352489 @default.
- W2955238051 creator A5058903008 @default.
- W2955238051 creator A5070281210 @default.
- W2955238051 creator A5090367295 @default.
- W2955238051 date "2019-06-01" @default.
- W2955238051 modified "2023-09-29" @default.
- W2955238051 title "A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris" @default.
- W2955238051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31251546" @default.
- W2955238051 hasPublicationYear "2019" @default.
- W2955238051 type Work @default.
- W2955238051 sameAs 2955238051 @default.
- W2955238051 citedByCount "6" @default.
- W2955238051 countsByYear W29552380512020 @default.
- W2955238051 countsByYear W29552380512021 @default.
- W2955238051 countsByYear W29552380512022 @default.
- W2955238051 countsByYear W29552380512023 @default.
- W2955238051 crossrefType "journal-article" @default.
- W2955238051 hasAuthorship W2955238051A5024204845 @default.
- W2955238051 hasAuthorship W2955238051A5027145121 @default.
- W2955238051 hasAuthorship W2955238051A5028916171 @default.
- W2955238051 hasAuthorship W2955238051A5043352489 @default.
- W2955238051 hasAuthorship W2955238051A5058903008 @default.
- W2955238051 hasAuthorship W2955238051A5070281210 @default.
- W2955238051 hasAuthorship W2955238051A5090367295 @default.
- W2955238051 hasConcept C126322002 @default.
- W2955238051 hasConcept C141071460 @default.
- W2955238051 hasConcept C16005928 @default.
- W2955238051 hasConcept C168563851 @default.
- W2955238051 hasConcept C197934379 @default.
- W2955238051 hasConcept C2777673923 @default.
- W2955238051 hasConcept C2778375690 @default.
- W2955238051 hasConcept C2779306117 @default.
- W2955238051 hasConcept C2780986958 @default.
- W2955238051 hasConcept C535046627 @default.
- W2955238051 hasConcept C71924100 @default.
- W2955238051 hasConcept C98274493 @default.
- W2955238051 hasConceptScore W2955238051C126322002 @default.
- W2955238051 hasConceptScore W2955238051C141071460 @default.
- W2955238051 hasConceptScore W2955238051C16005928 @default.
- W2955238051 hasConceptScore W2955238051C168563851 @default.
- W2955238051 hasConceptScore W2955238051C197934379 @default.
- W2955238051 hasConceptScore W2955238051C2777673923 @default.
- W2955238051 hasConceptScore W2955238051C2778375690 @default.
- W2955238051 hasConceptScore W2955238051C2779306117 @default.
- W2955238051 hasConceptScore W2955238051C2780986958 @default.
- W2955238051 hasConceptScore W2955238051C535046627 @default.
- W2955238051 hasConceptScore W2955238051C71924100 @default.
- W2955238051 hasConceptScore W2955238051C98274493 @default.
- W2955238051 hasIssue "6" @default.
- W2955238051 hasLocation W29552380511 @default.
- W2955238051 hasOpenAccess W2955238051 @default.
- W2955238051 hasPrimaryLocation W29552380511 @default.
- W2955238051 hasRelatedWork W2086418510 @default.
- W2955238051 hasRelatedWork W3034002680 @default.
- W2955238051 hasRelatedWork W3109258365 @default.
- W2955238051 hasRelatedWork W3109327948 @default.
- W2955238051 hasRelatedWork W3197329460 @default.
- W2955238051 hasRelatedWork W3213881064 @default.
- W2955238051 hasRelatedWork W4210478377 @default.
- W2955238051 hasRelatedWork W4252078926 @default.
- W2955238051 hasRelatedWork W4285045938 @default.
- W2955238051 hasRelatedWork W4286592295 @default.
- W2955238051 hasVolume "18" @default.
- W2955238051 isParatext "false" @default.
- W2955238051 isRetracted "false" @default.
- W2955238051 magId "2955238051" @default.
- W2955238051 workType "article" @default.